Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro

Current cancer drug targets, 2010 - ingentaconnect.com
The efficacy of cancer-immunotherapy with complement-activating monoclonal antibodies is
limited by over-expression of one or more membrane-bound complement regulatory …
被引用次数：66 相关文章

Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro

N Geis, S Zell, R Rutz, W Li, T Giese… - … cancer drug targets, 2010 - pubmed.ncbi.nlm.nih.gov
The efficacy of cancer-immunotherapy with complement-activating monoclonal antibodies is
limited by over-expression of one or more membrane-bound complement regulatory …

Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.

N Geis, S Zell, R Rutz, W Li, T Giese… - Current Cancer Drug …, 2010 - europepmc.org
The efficacy of cancer-immunotherapy with complement-activating monoclonal antibodies is
limited by over-expression of one or more membrane-bound complement regulatory …
[PDF] researchgate.net

[PDF][PDF] Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro

N Geis, S Zell, R Rutz, W Li, T Giese… - Current Cancer Drug …, 2010 - researchgate.net
Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA
Sensitizes Tumor Cells to Complement Attack I Page 1 Current Cancer Drug Targets, 2010, 10 …